WeVote
Log In

Bill

Bill

S 4194

Revises certain requirements for prescription of Schedule II controlled dangerous substances via telemedicine and telehealth without in-person examination or review.*

2026-2027 Regular Session Introduced by Vin Gopal and 2 co-sponsors

Allows prescribing Schedule II controlled substances via telemedicine without in-person exam, with safety, documentation, and oversight requirements.

Reported from Senate Committee as a Substitute, 2nd Reading
0
WeVote Research Nonpartisan
Bill Summary · S 4194

Summary of Bill S 4194 (New Jersey, Session 222)

Title

Permits prescription of Schedule II controlled dangerous substances via telemedicine and telehealth without in-person examination or review.

Purpose and intent

  • To authorize clinicians to prescribe Schedule II controlled dangerous substances (CDS) through telemedicine and telehealth platforms without requiring an in-person examination or prior in-person review.
  • Aims to improve access to essential medications for patients who may have barriers to in-person visits, while providing a framework for safety and oversight.

Key provisions and changes

  • Telemedicine prescribing authority expanded:

    • Allows a prescriber to issue prescriptions for Schedule II CDS (e.g., certain opioid medications, stimulants) through telemedicine or telehealth without an in-person evaluation.
    • The bill outlines circumstances, safeguards, and requirements to ensure legitimate medical use and to mitigate misuse.

  • Clinical and safety safeguards (highlights; specifics depend on statutory text):

    • Prescriptions must be issued within the standard medical practice and patient-specific assessment conducted via telemedicine.
    • Compliance with existing federal and state regulations governing CDS prescribing, including patient identification, medical history review, and monitoring protocols.
    • Potential requirements for periodic in-person assessments or follow-up visits, or the use of Telemedicine verifications and record-keeping to document medical necessity and continuity of care.

  • Recordkeeping and reporting:

    • Prescribers must maintain appropriate documentation for telemedicine CDS prescriptions, consistent with general prescribing and CDS control laws.
    • Possible reporting to state-controlled dangerous substances monitoring programs or similar registries as applicable.

  • Scope and applicability:

    • Applies to licensed prescribers authorized to prescribe CDS in New Jersey.
    • Specifies the types of telemedicine encounters (real-time audio-visual platforms vs. other modalities, if applicable) and any technology or security standards required.

  • Coordination with other laws:

    • Aligns with federal DEA regulations and state CDS statutes, ensuring no conflicts with mandatory in-person evaluations where required by federal or state law.
    • May include sunset provisions, review requirements, or accountability mechanisms to reassess telemedicine CDS prescribing practices.

Who is affected

  • Healthcare providers: Clinicians licensed in New Jersey who prescribe Schedule II CDS; subject to telemedicine-specific procedures and ongoing professional standards.
  • Patients: Individuals needing Schedule II CDS who may benefit from telemedicine access, including those with barriers to in-person visits.
  • Regulatory and oversight bodies: State medical boards, licensing authorities, and any CDS monitoring registries involved in compliance verification, audits, and enforcement.
  • Payers and health systems: Insurers and healthcare organizations implementing telemedicine practices and documentation standards for CDS prescriptions.

Procedural and timeline aspects

  • Effective date and transition: The bill would specify when the new telemedicine CDS prescribing authority becomes effective and any phased implementation steps.
  • Regulatory alignment: Likely requires rulemaking or guidance from relevant state agencies to detail procedures, forms, and recordkeeping standards.
  • Oversight and sunset provisions: The bill may include provisions for periodic review by the legislature or the relevant boards to assess impact, safety, and unintended consequences; possible sunset or renewal requirements if applicable.
  • Enforcement and penalties: Establishes consequences for noncompliance with telemedicine CDS prescribing rules, consistent with existing CDS statutes and medical discipline processes.

Notes

  • The sponsor list includes Co-sponsors Vin Gopal and Joe Vitale.
  • The summary reflects typical elements of a bill of this nature; exact language may specify additional conditions, exemptions, and procedural steps. For precise provisions, consult the bill text and any accompanying committee reports.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.